US 20210236494A1

(19) United States

(12) Patent Application Publication

Williams et al.

(10) Pub. No.: US 2021/0236494 A1

(43) Pub. Date: Aug. 5, 2021

(54) **THERAPEUTIC COMBINATION**

(71) Applicant: **Oncologica UK Ltd.**, Chesterford, Cambridge (GB)

(72) Inventors: **Gareth Williams**, Ely, Cambridgeshire (GB); **Marco Loddo**, Saffron Walden, Essex (GB)

(21) Appl. No.: **17/052,006**

(22) PCT Filed: **May 1, 2019**

(86) PCT No.: **PCT/GB2019/051205**

§ 371 (c)(1),
(2) Date: **Oct. 30, 2020**

(30) **Foreign Application Priority Data**

May 1, 2018 (GB) 1807147.2

Publication Classification

(51) **Int. Cl.**

A61K 31/513	(2006.01)
A61K 31/337	(2006.01)
A61K 45/06	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/513*** (2013.01); ***A61K 45/06*** (2013.01); ***A61K 31/337*** (2013.01)

(57) **ABSTRACT**

There is provided a combination of agents which allow normal cells to be reversibly arrested in G1 phase thereby shielding them from the toxic effects of cytotoxic agents used to kill cancer cells in cancer treatment.

Specification includes a Sequence Listing.